Viveve Medical (NASDAQ:VIVE) a medical technology company focused on women’s intimate health, today announced positive 12-month data from an investigator-initiated, single-arm, 12-month feasibility study using its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform for the treatment of mild-to-moderate stress urinary incontinence (SUI) in women. As quoted in the press release: The study was conducted by Bruce … Continued
The post Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study appeared first on Investing News Network.